The obligation to provide antiretroviral treatment in HIV prevention trials.
Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials.
Lo
Bernard
B
Program in Medical Ethics, Center for AIDS Prevention Studies and Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA.
Padian
Nancy
N
Barnes
Mark
M
D044966:Anti-Retroviral Agents / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000941:ethics*; D003906:Developing Countries; D005381:Financing, Organized / Q000941:ethics / Q000379:methods; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*; D006679:HIV Seropositivity / Q000188:drug therapy; D017048:Health Care Costs / Q000941:ethics; D006297:Health Services Accessibility / Q000941:ethics; D006801:Humans
D044966:Anti-Retroviral Agents